OR WAIT null SECS
November 13, 2023
Video
David Lally, MD describes individual phenotypic features in geographic atrophy and determining patient response to treatment.
Veeral Sheth, MD, MBA, discusses how clinicians are beginning to use these therapies and the patient reaction to the availability of treatments for GA.
Veeral Sheth, MD, MBA, discusses the clinical trial data that led to FDA approval of SYFOVRE and IZERVAY for geographic atrophy.
David Lally, MD describes the association of the complement system with geographic atrophy and how the 2 FDA-approved therapies for GA work to block the complement system.
Veeral Sheth, MD discusses the two newly FDA-approved therapies for geographic atrophy: pegcetacoplan injection (SYFOVRE) and avacincaptad pegol (IZERVAY).
David Lally, MD, discusses biomarkers for the progression of geographic atrophy and the lack of previous treatment options for the disease.
Veeral Sheth, MD, MBA describes the presentation of geographic atrophy in patients and how they are first affected by the disease.
David Lally, MD describes the hallmark features of geographic atrophy and how the disease develops over time.
November 10, 2023
Phase 3 results from the GATHER2 trial show the treatment effect of avacincaptad pegol for geographic atrophy more than doubled over 2 years compared to year 1 of study.
November 05, 2023
Presented at AAO 2023, new 3-year data from the GALE extension study shows increasing treatment effects over time with pegcetacoplan injection for geographic atrophy.